Dynavax Technologies Corp. DVAX

NAS: DVAX | ISIN: US2681582019   9/02/2026
15,50 USD (0,00%)
(0,00%)   9/02/2026

24 december 2025 · Sanofi to Acquire Dynavax, Adding a Marketed Adult Hepatitis B Vaccine and Phase 1/2 Shingles Candidate to the Pipeline · Persbericht

19 november 2025 · Dynavax to Participate at the 8th Annual Evercore Healthcare Conference · Persbericht

5 november 2025 · Dynavax Reports Third Quarter 2025 Financial Results and Announces New $100 Million Share Repurchase Program · Persbericht

5 november 2025 · Dynavax Enters Exclusive License Agreement for Vaxart's Novel Oral COVID-19 Vaccine Program · Persbericht

22 oktober 2025 · Dynavax to Report Third Quarter 2025 Financial Results and Host Conference Call on November 5, 2025 · Persbericht

21 oktober 2025 · Dynavax Presents Positive Topline Data from Part 1 of Phase 1/2 Trial for Shingles Vaccine Candidate at IDWeek 2025 and Announces Initiation of Part 2 of Trial · Persbericht

27 augustus 2025 · Dynavax to Participate in the 2025 Wells Fargo Healthcare Conference · Persbericht

21 augustus 2025 · Dynavax Announces Positive Topline Phase 1/2 Results Supporting Potential Best-in-Class Shingles Vaccine Profile · Persbericht

7 augustus 2025 · Dynavax Reports Second Quarter 2025 Financial Results · Persbericht

29 juli 2025 · Dynavax to Report Second Quarter 2025 Financial Results and Host Conference Call on August 7, 2025 · Persbericht

11 juni 2025 · Dynavax Stockholders Elect All Dynavax Director Nominees at 2025 Annual Meeting · Persbericht

9 juni 2025 · Dynavax Urges Stockholders to Support Its Director Nominees at June 11 Annual Meeting · Persbericht

4 juni 2025 · Dynavax Comments on Glass Lewis Recommendation · Persbericht

28 mei 2025 · Dynavax to Present at William Blair's 45th Annual Growth Stock Conference · Persbericht

23 mei 2025 · Leading Independent Proxy Advisory Firm ISS Recommends Stockholders Vote "FOR" All Four of Dynavax's Highly Qualified Director Nominees · Persbericht

12 mei 2025 · Dynavax Files Investor Presentation Highlighting Superior Strategy and Board That is Delivering Strong Financial Results and Significant Long-Term Value · Persbericht

10 mei 2025 · /C O R R E C T I O N -- Dynavax Technologies/ · Persbericht

7 mei 2025 · Dynavax Issues Statement and Mails Letter to Stockholders Emphasizing Record Financial Results and Continued Momentum · Persbericht

6 mei 2025 · Dynavax Reports First Quarter 2025 Financial Results and Announces New Pipeline Programs · Persbericht

1 mei 2025 · Dynavax Announces Nationwide Harris Poll Survey Results Finding Americans Underestimate the Serious Consequences of Hepatitis B and Vaccine Protection Benefits · Persbericht

Mijn selecties